AffyImmune Therapeutics

Biotechnology startup developing Tune & Track platform to expand utility & improve safety of CAR T therapy for cancer.

[AffyImmune Therapeutics @affyimmune]

AffyImmune Therapeutics Appoints Deyaa Adib, MD as Chief Medical Officer: https://t.co/ZqnZQsv693

[AffyImmune Therapeutics @affyimmune]

AffyImmune Appoints Drs. Rick Rutter and Jorge Nieva to Board of Directors

The addition of these leaders in clinical development and manufacturing strengthens AffyImmune’s commitment to advancing its AIC100 program in #thyroidcancer and #NSCLC.

https://t.co/KXBIhtRNjL

[AffyImmune Therapeutics @affyimmune]

Our CEO Daniel Janse is speaking on the Funding Biotech Innovation and Scaling up panel at @LSXLeaders #LSXWorldCongress

[AffyImmune Therapeutics @affyimmune]

.@CancerNetwrk covers our recent RMAT designation for our CAR T therapy in #thyroidcancer.

https://t.co/HenmpHjaXc

[AffyImmune Therapeutics @affyimmune]

Pharmaceutical Business Review covers our recent RMAT designation in #thyroid cancer:

https://t.co/jE47h48LhU

[Big4Bio @big4bio]

Announced Today: @affyimmune Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AIC100 in Recurrent Anaplastic Thyroid Cancer

More: https://t.co/6EIPmONLKy

#lifesciences #biotech #thyroidcancer #FDA

[AffyImmune Therapeutics @affyimmune]

AffyImmune Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AIC100 in Recurrent Anaplastic #Thyroid Cancer

Read the release:

https://t.co/rQvbW85SoB

[ReadMagazine @Read_Magazine21]

@affyimmune Appoints Dr. Daniel Janse as Chief Executive Officer

https://t.co/PkOvEzC7JN

#Readmagazine #news #industries #Artificialintelligence #biotechnology #affyimmune #CARTcelltherapies

[AffyImmune Therapeutics @affyimmune]

We’re excited to announce the appointment of Dr. Daniel Janse as President & CEO. Dr. Janse brings 20 years of expertise and an extensive background in #biopharma research and development, operations, and leadership.

Read the release:

https://t.co/0VlKUS5giW

[AffyImmune Therapeutics @affyimmune]

Thanks @BioPharmReport for speaking with our CEO @mattbritz at #ASCO24 for this Q&A:

https://t.co/vFQDrXo0jb

[DelveInsight @delve_insight]

ASCO 2024: Anticipation mounts for the latest advancements in cancer treatment.

Key companies, @AstraZeneca @DaiichiSankyoUS @Merck @affyimmune @Genmab, and others are prepared to unveil highlights in Head and Neck Cancer.

For More: https://t.co/wkFAoC4tGR
#ASCO2024

[FirstWord Pharma @fwpharma]

AffyImmune’s CAR-T sees first-ever complete response in solid tumour $AFFY #ASCO24 https://t.co/youC6W0cA2

[pharmaphorum @pharmaphorum]

. @AffyImmune has recorded what it says is the first complete response in a patient with a solid tumour treated with CAR-T therapy at #ASCO24. #thyroidcancer

https://t.co/6XOdF15pAB

[AffyImmune Therapeutics @affyimmune]

For evaluable patients in DL2 (100 million CAR T cells) and DL3 (500m CAR T cells) (n=6), the ORR was 33%, with one pt at DL2 achieving a durable partial response (PR) and another patient at DL3 achieving an ongoing durable mCR allowing the pt to be off all chemo. DCR was 67%.

[AffyImmune Therapeutics @affyimmune]

Excited to share our upcoming poster presentation at #ASCO24 @ASCO
where we will present a confirmed complete response in a patient with Anaplastic #Thyroid Cancer with our autologous CAR T therapy AIC100.

https://t.co/U0hd8jNaCg

[AffyImmune Therapeutics @affyimmune]

As of the data cutoff date, 10 patients (6 ATC; 4 PDTC) were infused with AIC100 at 3 dose levels (DLs). No dose-limiting toxicities were observed across all dose levels, and the maximum tolerated dose was not reached.

[AffyImmune Therapeutics @affyimmune]

Excited to announce our presentation at @ASCO 2024 about our affinity-tuned CAR T therapy AIC100. #ASCO24

Read the full release:

https://t.co/HmBo7MdO8q

[OncoDaily @oncodaily]

I'm very pleased to serve on the Clinical and Regulatory Advisory Board of @affyimmune - Hagop Youssoufian

#Cancer #Career #CARTTherapies #LungCancer #OncoDaily #Oncology #ThyroidCancer #Biotechnology

https://t.co/amQivKZXVh

[AffyImmune Therapeutics @affyimmune]

AffyImmune Presents Preclinical Data on AIC100 Affinity-Tuned CAR T Targeting ICAM-1 in Additional Solid Tumor Types at #AACR24 @AACR

https://t.co/1M9YfdaWFx

[AffyImmune Therapeutics @affyimmune]

Excited to announce the formation of our Clinical and Regulatory Advisory Board today:

https://t.co/pzm7pvvLuz